All News

Surgery and radiation yield similar cancer outcomes for low-risk prostate cancer, but higher-risk cases may require combining treatments, experts said.

I was told I wouldn’t live to see my daughters’ weddings — but 12 years later, I’ve been there for two, and I’m holding out hope for the third.

Treating patients with lung cancer always calls for a focus on informed and shared decision-making, according to expert oncologists.

The FDA granted fast track designation to RAD101, an experimental imaging agent, to improve detection of recurrent brain metastases.

Dr. Joshua K. Sabari and Dr. Prantesh Jain delve into key lung cancer outcomes from the 2025 ASCO Meeting that patients should be aware of.

Keytruda was approved for locally advanced head and neck cancer before and after surgery, showing improved event-free survival versus standard care.

Joining support groups after cancer treatment helped me heal emotionally, connect with others who understood and embrace a new, meaningful normal.

Expert oncologists Dr. Joshua K. Sabari and Dr. Eric K. Singhi break down key updates and takeaways in lung cancer treatment following ASCO 2025.

Facing two life-threatening diagnoses, I overcame fear of self-injections by leaning on love, encouragement and determination to save my life.

Eminem’s lyric about having “one shot” stayed with me, and writing this letter to my newly diagnosed self, reminds me how that mindset saved my life.

Dr. Joshua K. Sabari and Dr. Daniel V. Araujo provide expert insights into genitourinary cancer updates from ASCO 2025.

FDA approves new Brukinsa tablet for five blood cancers, offering simpler dosing with the same safety and effectiveness as capsules.

Dr. Michael Serzan provides expert takeaways on treatment updates for patients with early-stage kidney cancer following the 2025 ASCO Meeting.

Being a cancer survivor for nine and a half years has taught me to live in the moment, to make those moments count.

Dr. Joshua K. Sabari sat down with Dr. Daniel V. Araujo to discuss topline takeaways from the 2025 ASCO Meeting across the realm of genitourinary oncology

The U.S. FDA has approved treatment with Ibtrozi for patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.

Two people connect by sharing their experiences about taking care of their spouses who died from cancer, and the realization that sparked something more.

Treatment with the investigational therapeutic rusfertide has proven to be a potential treatment option for patients with polycythemia vera.

FDA granted priority review to Zepzelca plus Tecentriq for first-line maintenance in extensive-stage small cell lung cancer.

Amanda Snyder, a cancer survivor, became an oncology nurse to provide support she once lacked, now leading innovative therapies for patients.

Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.

Dr. Suresh Ramalingam discusses how Tagrisso has ushered in a new era of care for patients with advanced EGFR+ non-small cell lung cancer.

I survived breast cancer and medical trauma, but the road was brutal. Fifteen years later, I’m alive, scarred and still searching for peace.

Dr. Mabel Mardones educates patients on breast cancer subtypes, as well as treatment options for those with ER-positive, HER2-negative disease.

The FDA grants fast track designation to PHST001, an antibody targeting CD24, for advanced platinum-resistant and platinum-sensitive ovarian cancer.

The VERIFY trial explores rusfertide to manage polycythemia vera without causing iron deficiency symptoms, Dr. Aaron Gerds explained.

Five years after my transplant for leukemia, I’m learning to focus on gratitude despite daily struggles, remembering that being alive is the greatest gift.

Michelle Kirschner discusses the how patients can foster a strong network of supporters from diagnosis through survivorship.